Literature DB >> 8053431

Diminished luminal release of esophageal epidermal growth factor in patients with reflux esophagitis.

R M Rourk1, Z Namiot, M C Edmunds, J Sarosiek, Z Yu, R W McCallum.   

Abstract

OBJECTIVES: It has recently been demonstrated that human esophageal mucosa, containing numerous submucosal mucous glands, has the ability to elaborate significant amounts of esophageal epidermal growth factor (eEGF). Because of its role in the maintenance of the integrity of the esophageal mucosa, we elected to study the rate of secretion of eEGF in patients with reflux esophagitis (RE), compared with controls, using our newly developed esophageal perfusion model.
METHODS: Fourteen healthy asymptomatic volunteers and 14 patients with endoscopically confirmed esophagitis underwent esophageal perfusion with saline, HCl (0.01 M, pH 2.1) HCl/pepsin (0.5 mg/ml of HCl), and ending NaCl solution during four consecutive 8-min perfusion periods. All perfusates were assayed for EGF by RIA (Amersham). Results are expressed as mean +/- SEM. Student's t test was used for statistical analysis.
RESULTS: The basal rate of luminal EGF release in patients with RE was 3.78 +/- 0.29 ng/min. This value significantly declined (2.27 +/- 0.27 ng/min; p < 0.001) during mucosal exposure to HCl but was significantly enhanced when the HCl perfusing solution was supplemented with pepsin (4.20 +/- 0.29; p < 0.001 vs. HCl). Introduction of saline during the last perfusion period maintained a rate of luminal EGF release similar to that observed during the initial esophageal perfusion with saline. Luminal release of EGF in patients with RE was significantly lower, compared with corresponding values recorded in controls during perfusion with saline (3.78 +/- 0.29 vs. 14.1 +/- 1.25 ng/min; p < 0.00001), with HCl (2.27 +/- 0.27 vs. 5.95 ng/min; p < 0.0001), with HCl/pepsin solution (4.2 +/- 0.29 vs. 11.7 +/- 1.88 ng/min; p < 0.0001), and during the final perfusion period with saline (3.73 +/- 0.25 vs. 15.1 +/- 1.1 ng/min; p < 0.00001). Therefore, the rate of luminal EGF release in controls was 4-fold, 3-fold, 3-fold, and 4-fold higher than that of patients with RE during perfusion with initial saline, HCl, HCl/pepsin and final saline, respectively.
CONCLUSIONS: 1) Decreased esophageal EGF in patients with RE may facilitate the development or delay the healing of mucosal injury. 2) Depletion of EGF from the mucus layer covering the epithelium under the impact of refluxed luminal acid/pepsin may be considered as one of the potential underlying mechanisms leading to damage of the esophageal mucosa during gastroesophageal reflux episodes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053431

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

1.  Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.

Authors:  Winson Y Cheung; Rihong Zhai; Matthew H Kulke; Rebecca S Heist; Kofi Asomaning; Clement Ma; Zhaoxi Wang; Li Su; Michael Lanuti; Kenneth K Tanabe; David C Christiani; Geoffrey Liu
Journal:  Carcinogenesis       Date:  2009-06-11       Impact factor: 4.944

2.  Necrotizing sialometaplasia-like change of the esophageal submucosal glands is associated with Barrett's esophagus.

Authors:  David R Braxton; Dana C Nickleach; Yuan Liu; Alton B Farris
Journal:  Virchows Arch       Date:  2014-05-27       Impact factor: 4.064

3.  Salivary bicarbonate as a major factor in the prevention of upper esophageal mucosal injury in gastroesophageal reflux disease.

Authors:  Tomasz Skoczylas; Harathi Yandrapu; Cezary Poplawski; Mazen Asadi; Grzegorz Wallner; Jerzy Sarosiek
Journal:  Dig Dis Sci       Date:  2014-03-09       Impact factor: 3.199

Review 4.  Environmental - lifestyle related factors.

Authors:  Sabine Roman; John E Pandolfino
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-12       Impact factor: 3.043

5.  Adaptation of esophageal mucosa to acid- and pepsin-induced damage: role of nitric oxide and epidermal growth factor.

Authors:  A I Lanas; J M Blas; J Ortego; J Soria; R Sáinz
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

6.  Impact of Helicobacter pylori colonization on immunoreactive epidermal growth factor and transforming growth factor-alpha in gastric juice. Its potential pathogenetic implications.

Authors:  M Marcinkiewicz; B Van Der Linden; D A Peura; G Goldin; S Parolisi; J Sarosiek
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

Review 7.  Pathophysiology of gastro-oesophageal reflux disease.

Authors:  F De Giorgi; M Palmiero; I Esposito; F Mosca; R Cuomo
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-10       Impact factor: 2.124

8.  Stimulated saliva secretion is reduced in proton pump inhibitor-resistant severe reflux esophagitis patients.

Authors:  Tomohide Tanabe; Mai Koeda; Yuichi Kitasako; Eri Momma; Yoshimasa Hoshikawa; Shintaro Hoshino; Noriyuki Kawami; Mitsuru Kaise; Katsuhiko Iwakiri
Journal:  Esophagus       Date:  2021-02-15       Impact factor: 4.230

9.  Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study.

Authors:  Ajoy Dias; Cesar Garcia; Marek Majewski; Grzegorz Wallner; Richard W McCallum; Cezary Poplawski; Jerzy Sarosiek
Journal:  Dig Dis Sci       Date:  2011-06-22       Impact factor: 3.199

10.  Role of saliva in esophageal defense: implications in patients with nonerosive reflux disease.

Authors:  Harathi Yandrapu; Marek Marcinkiewicz; Cezary Poplawski; Kyung Han; Tomasz Zbroch; George Goldin; Irene Sarosiek; Zbigniew Namiot; Jerzy Sarosiek
Journal:  Am J Med Sci       Date:  2015-05       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.